Aptevo Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APVO research report →
Companywww.aptevotherapeutics.com
Aptevo Therapeutics Inc. , a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.
- CEO
- Jeffrey G. Lamothe
- IPO
- 2016
- Employees
- 37
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $9.96M
- P/E
- -0.18
- P/S
- 0.00
- P/B
- 0.42
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -198.50%
- ROIC
- -166.33%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-25,967,000 · -7.61%
- EPS
- $-87.27 · 99.72%
- Op Income
- $-26,312,000
- FCF YoY
- -7.60%
Performance & Tape
- 52W High
- $258.12
- 52W Low
- $3.80
- 50D MA
- $4.72
- 200D MA
- $17.17
- Beta
- 1.64
- Avg Volume
- 52.88K
Get TickerSpark's AI analysis on APVO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 25 | Grant Grady III | buy | 13,513 |
| Oct 1, 25 | BANK OF AMERICA CORP /DE/ | other | 0 |
| Sep 30, 25 | BANK OF AMERICA CORP /DE/ | other | 0 |
| Aug 6, 25 | Abdun-Nabi Daniel | other | 7,200 |
| Aug 6, 25 | Taylor Daphne | other | 11,500 |
| Aug 6, 25 | Grant Grady III | other | 7,200 |
| Aug 6, 25 | Huebner Dirk | other | 11,500 |
| Aug 6, 25 | Niederhuber John | other | 7,200 |
| Aug 6, 25 | Lamothe Jeffrey G. | other | 17,300 |
| Aug 6, 25 | White Marvin L | other | 30,000 |
Our APVO Coverage
We haven't published any research on APVO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate APVO Report →